SOTIO Biotech expands collaboration with Synaffix for Bispecific ADC Development
Synaffix continues to drive innovation in the ADC space. SOTIO Biotech has announced it will be exercising its option with Synaffix to develop two bispecific antibody-drug conjugate (ADC) programs.
Under this agreement, SOTIO will leverage Synaffix’s proprietary GlycoConnect®, HydraSpace®, and linker-payload platforms to advance the development of these promising bispecific ADC candidates. This expansion highlights the strength of Synaffix’s clinically validated technology and its growing impact in the field of targeted cancer therapeutics.
Peter Van de Sande, Head of Synaffix, stated:
“We are pleased that SOTIO recognizes the versatility and robustness of our ADC platform and has chosen to expand its use to two additional targets. Bispecific ADCs are a key part of our offering, and we are excited to support this next stage of innovation in targeted cancer treatment.”
Read more here.
Find more news here.